At the molecular level, the Lynch syndrome is distinguished by sporadic MSI-high colorectal cancers because acquired CpG methylation of the MLH1 promoter and V600E mutation of the BRAF gene are frequently observed in the latter, but not in the former. The gene discussed is BRAF; the disease is colorectal cancer.